Verona Pharma plc Quarterly Balance Sheets Chart
Quarterly
|
Annual
Verona Pharma plc Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||
| current assets: | ||||||||||||||||||
| cash and cash equivalents | 438,016,000 | 401,415,000 | 399,757,000 | 336,040,000 | 404,599,000 | 271,772,000 | 257,366,000 | 270,727,000 | 291,415,000 | 227,827,000 | 231,701,000 | 111,510,000 | 132,764,000 | 148,380,000 | 166,547 | 146,035,000 | 169,598,000 | 187,986,000 |
| accounts receivable | 82,858,000 | 62,159,000 | 31,496,000 | 6,904,000 | 25,002,000 | |||||||||||||
| prepaid expenses | 11,432,000 | 11,317,000 | 7,573,000 | 7,964,000 | 5,433,000 | 3,617,000 | 3,332,000 | 894,000 | 1,561,000 | 2,499,000 | 3,355,000 | 4,731,000 | 1,246,000 | 4,037,000 | 6,672 | 9,817,000 | 7,247,000 | 4,538,000 |
| tax incentive receivable | 4,061,000 | 5,935,000 | 5,762,000 | 5,587,000 | 3,684,000 | 9,510,000 | 10,150,000 | 11,842,000 | ||||||||||
| inventory | 8,612,000 | 7,244,000 | 6,249,000 | 4,315,000 | ||||||||||||||
| other current assets | 3,872,000 | 12,955,000 | 2,735,000 | 3,443,000 | 2,576,000 | 3,365,000 | 6,319,000 | 6,060,000 | 2,073,000 | 3,388,000 | 3,077,000 | 2,206,000 | 2,525,000 | 2,063,000 | 667 | 2,320,000 | 1,484,000 | 1,720,000 |
| total current assets | 548,851,000 | 501,025,000 | 453,572,000 | 364,253,000 | 416,292,000 | 289,708,000 | 276,527,000 | 287,831,000 | 306,891,000 | 242,996,000 | 258,454,000 | 138,632,000 | 152,955,000 | 170,063,000 | 184,492 | 216,283,000 | 188,601,000 | |
| non-current assets: | ||||||||||||||||||
| furniture and equipment | 991,000 | 1,048,000 | 1,105,000 | 40,000 | 44,000 | 24,000 | 10,000 | 11,000 | 12,000 | 73,000 | 81,000 | 91,000 | 71,000 | 80,000 | 88 | 89,000 | 98,000 | 107,000 |
| inventory, long-term | 5,910,000 | 6,508,000 | 1,972,000 | |||||||||||||||
| goodwill | 545,000 | 545,000 | 545,000 | 545,000 | 545,000 | 545,000 | 545,000 | 545,000 | 545,000 | 545,000 | 544,000 | 545,000 | 545,000 | 545,000 | 545 | 545,000 | 545,000 | 545,000 |
| equity interest | 15,000,000 | 15,000,000 | 15,000,000 | 15,000,000 | 15,000,000 | 15,000,000 | 15,000,000 | 15,000,000 | 15,000,000 | 15,000,000 | 15,000,000 | 15,000,000 | 15,000,000 | 15,000,000 | 15,000 | |||
| right-of-use assets | 1,574,000 | 1,810,000 | 2,048,000 | 1,980,000 | 2,242,000 | 2,847,000 | 388,000 | 542,000 | 698,000 | 854,000 | 793,000 | 588,000 | 744,000 | 899,000 | 1,435 | 1,585,000 | 906,000 | 1,050,000 |
| total non-current assets | 24,020,000 | 24,911,000 | 20,670,000 | 17,565,000 | 17,831,000 | 15,943,000 | 16,098,000 | 16,255,000 | 16,418,000 | 16,224,000 | 16,360,000 | 17,068 | 2,219,000 | 1,549,000 | ||||
| total assets | 572,871,000 | 525,936,000 | 474,242,000 | 381,818,000 | 434,123,000 | 308,124,000 | 292,470,000 | 303,929,000 | 323,146,000 | 259,468,000 | 274,872,000 | 154,856,000 | 169,315,000 | 186,587,000 | 201,560 | 218,502,000 | 190,150,000 | 204,206,000 |
| liabilities and shareholders’ equity | ||||||||||||||||||
| current liabilities: | ||||||||||||||||||
| accounts payable | 3,434,000 | 9,077,000 | 11,266,000 | 6,831,000 | 4,152,000 | 3,492,000 | 823,000 | 2,493,000 | 7,237,000 | 2,910,000 | 8,002,000 | 9,364,000 | 8,064,000 | 10,044,000 | 9 | 34,000 | 541,000 | 178,000 |
| accrued expenses | 43,328,000 | 32,335,000 | 16,757,000 | 18,143,000 | 19,630,000 | 3,585,000 | 7,397,000 | 7,467,000 | 17,703,000 | 13,752,000 | 22,978,000 | 28,603,000 | 28,877,000 | 22,256,000 | 26,457 | 17,188,000 | 8,514,000 | 10,863,000 |
| royalties payable | 3,088,000 | 4,487,000 | 1,100,000 | 169,000 | ||||||||||||||
| revenue interest purchase security agreement | 102,019,000 | 96,338,000 | ||||||||||||||||
| current operating lease liabilities | 1,014,000 | 1,078,000 | 1,120,000 | 952,000 | 1,031,000 | 1,180,000 | 376,000 | 545,000 | 650,000 | 675,000 | ||||||||
| taxes payable | 8,889,000 | 8,889,000 | 1,011,000 | 1,011,000 | 424,000 | 283,000 | 285,000 | 311,000 | 235,000 | 147,000 | 397 | |||||||
| other current liabilities | 374,000 | 678,000 | 2,862,000 | 844,000 | 1,200,000 | 435,000 | 416,000 | 444,000 | 509,000 | 1,409,000 | 294,000 | 121,000 | 144,000 | 327,000 | 185 | 300,000 | 133,000 | 118,000 |
| total current liabilities | 51,238,000 | 56,544,000 | 42,681,000 | 27,950,000 | 48,346,000 | 8,692,000 | 9,012,000 | 10,949,000 | 26,523,000 | 19,029,000 | 32,128,000 | 38,863,000 | 37,903,000 | 33,422,000 | 27,740 | 58,364,000 | 12,698,000 | 14,203,000 |
| non-current liabilities: | ||||||||||||||||||
| term loan | 242,434,000 | 241,742,000 | 120,341,000 | 120,009,000 | 119,687,000 | 48,374,000 | 19,905,000 | 19,857,000 | 19,809,000 | 9,768,000 | 5,035,000 | 4,981,000 | 4,928,000 | 4,874,000 | 4,821 | 4,767,000 | 4,685,000 | 4,635,000 |
| non-current operating lease liabilities | 926,000 | 1,055,000 | 1,241,000 | 1,349,000 | 1,478,000 | 1,775,000 | 20,000 | 30,000 | 65,000 | 205,000 | ||||||||
| total non-current liabilities | 243,360,000 | 242,797,000 | 227,002,000 | 223,377,000 | 217,503,000 | 50,149,000 | 19,925,000 | 19,887,000 | 19,874,000 | 9,973,000 | 5,259,000 | 5,113,000 | 5,105,000 | 5,160,000 | 5,618 | 5,741,000 | 5,038,000 | 5,149,000 |
| total liabilities | 294,598,000 | 299,341,000 | 269,683,000 | 251,327,000 | 265,849,000 | 58,841,000 | 28,937,000 | 30,836,000 | 46,397,000 | 29,002,000 | 37,387,000 | 43,976,000 | 43,008,000 | 38,582,000 | 33,358 | 64,105,000 | 17,736,000 | 19,352,000 |
| commitments and contingencies | ||||||||||||||||||
| shareholders' equity: | ||||||||||||||||||
| ordinary £0.05 par value shares; 703,189,462 and 703,189,462 issued, and 687,930,486 and 677,008,254 outstanding, at june 30, 2025 and december 31, 2024, respectively | 45,021,000 | |||||||||||||||||
| additional paid-in capital | 805,918,000 | 766,369,000 | 728,199,000 | 621,628,000 | 616,618,000 | 601,063,000 | 601,180,000 | 596,059,000 | 590,915,000 | 529,187,000 | 525,858,000 | 390,543,000 | 388,204,000 | 385,070,000 | 382,005 | 379,282,000 | 375,261,000 | 366,411,000 |
| ordinary shares held in treasury | -964,000 | -1,402,000 | -1,659,000 | -828,000 | -1,203,000 | -1,517,000 | -746,000 | -975,000 | -1,208,000 | -1,549,000 | -449,000 | -591,000 | -739,000 | -603,000 | -770 | -843,000 | -1,670,000 | -1,700,000 |
| accumulated other comprehensive loss | -4,601,000 | -4,601,000 | -4,601,000 | -4,601,000 | -4,601,000 | -4,601,000 | -4,601,000 | -4,601,000 | -4,601,000 | -4,601,000 | -4,601,000 | -4,601,000 | -4,601,000 | -4,601,000 | -4,601 | -4,601,000 | -4,601,000 | -4,601,000 |
| accumulated deficit | -567,101,000 | -578,792,000 | -562,401,000 | -528,479,000 | -485,311,000 | -388,433,000 | -374,053,000 | -359,143,000 | -350,110,000 | -333,097,000 | -322,442,000 | -306,653,000 | -288,739,000 | -263,716,000 | -240,287 | -251,265,000 | -228,370,000 | -207,050,000 |
| total shareholders' equity | 278,273,000 | 226,595,000 | 204,559,000 | 130,491,000 | 168,274,000 | 249,283,000 | 263,533,000 | 273,093,000 | 276,749,000 | 230,466,000 | 237,485,000 | 110,880,000 | 126,307,000 | 148,005,000 | 168,202 | 154,397,000 | 172,414,000 | 184,854,000 |
| total liabilities and shareholders' equity | 572,871,000 | 525,936,000 | 474,242,000 | 381,818,000 | 434,123,000 | 308,124,000 | 292,470,000 | 303,929,000 | 323,146,000 | 259,468,000 | 274,872,000 | 154,856,000 | 169,315,000 | 186,587,000 | 201,560 | 218,502,000 | 190,150,000 | 204,206,000 |
| ordinary £0.05 par value shares; 703,189,462 and 703,189,462 issued, and 681,056,022 and 677,008,254 outstanding, at march 31, 2025 and december 31, 2024, respectively | 45,021,000 | |||||||||||||||||
| revenue interest purchase and sale agreement | 687,000 | |||||||||||||||||
| ordinary £0.05 par value shares: 703,189,462 and 667,659,630 issued, and 677,008,254 and 643,536,094 outstanding, at december 31, 2024 and 2023, respectively | 45,021,000 | |||||||||||||||||
| ordinary £0.05 par value shares; 667,659,630 and 667,659,630 issued, and 654,649,358 and 643,536,094 outstanding, at september 30, 2024 and december 31, 2023, respectively | 42,771,000 | |||||||||||||||||
| license agreement obligations | 21,322,000 | |||||||||||||||||
| ordinary £0.05 par value shares; 667,659,630 and 667,659,630 issued, and 648,654,174 and 643,536,094 outstanding, at june 30, 2024 and december 31, 2023, respectively | 42,771,000 | |||||||||||||||||
| tax incentive receivables | 10,954,000 | 9,282,000 | 15,583,000 | |||||||||||||||
| total non-current assets: | 18,416,000 | 16,472,000 | 16,524,000 | 1,702,000 | ||||||||||||||
| shareholders' equity | ||||||||||||||||||
| ordinary £0.05 par value shares: 667,659,630 and 631,338,246 issued, and 643,536,094 and 606,301,054 outstanding, at december 31, 2023 and 2022, respectively | 42,771,000 | |||||||||||||||||
| ordinary £0.05 par value shares; 651,659,630 and 631,338,246 issued, and 639,520,054 and 606,301,054 outstanding, at september 30, 2023 and december 31, 2022, respectively | 41,753,000 | |||||||||||||||||
| ordinary £0.05 par value shares; 651,659,630 and 631,338,246 issued, and 635,787,302 and 606,301,054 outstanding, at june 30, 2023 and december 31, 2022, respectively | 41,753,000 | |||||||||||||||||
| ordinary £0.05 par value shares; 651,659,630 and 631,338,246 issued, and 631,987,078 and 606,301,054 outstanding, at march 31, 2023 and december 31, 2022, respectively | 41,753,000 | |||||||||||||||||
| ordinary £0.05 par value shares: 631,338,246 and 489,177,550 issued, and 606,301,054 and 480,082,966 outstanding, at december 31, 2022 and 2021, respectively | 40,526,000 | |||||||||||||||||
| tax and tax incentive receivable | 20,321,000 | 20,185,000 | 16,420,000 | 10,606 | ||||||||||||||
| operating lease liability | 569,000 | 464,000 | 583,000 | 648,000 | 690 | 749,000 | 757,000 | 798,000 | ||||||||||
| ordinary £0.05 par value shares; 608,138,246 and 489,177,550 issued, and 602,215,606 and 480,082,966 outstanding, at september 30, 2022 and december 31, 2021, respectively | 39,119,000 | |||||||||||||||||
| ordinary £0.05 par value shares; 494,058,246 and 489,177,550 issued, and 485,298,326 and 480,082,966 outstanding, at june 30, 2022 and december 31, 2021, respectively | 32,182,000 | |||||||||||||||||
| ordinary £0.05 par value shares; 494,058,246 and 489,177,550 issued, and 482,944,390 and 480,082,966 outstanding, at march 31, 2022 and december 31, 2021, respectively | 32,182,000 | |||||||||||||||||
| warrants | 2 | 42,000 | 2,753,000 | 2,246,000 | ||||||||||||||
| ordinary £0.05 par value shares: 489,177,550 and 488,304,446 issued, and 480,082,966 and 463,304,446 outstanding, at december 31, 2021 and 2020, respectively | 31,855,000 | |||||||||||||||||
| ordinary £0.05 par value shares; 489,177,550 and 488,304,446 issued, and 477,649,646 and 463,304,446 outstanding, at september 30, 2021 and december 31, 2020, respectively | 31,855 | |||||||||||||||||
| tax and tax incentive receivables | 14,108,000 | 10,272,000 | 8,260,000 | |||||||||||||||
| contract asset | 4,001,000 | |||||||||||||||||
| equity interest receivable | 15,000,000 | |||||||||||||||||
| deferred revenue | 40,051,000 | |||||||||||||||||
| ordinary £0.05 par value shares; 488,739,150 and 488,304,446 issued, and 471,839,302 and 463,304,446 outstanding, at june 30, 2021 and december 31, 2020, respectively | 31,824,000 | |||||||||||||||||
| ordinary £0.05 par value shares; 488,304,446 and 488,304,446 issued, and 463,745,750 and 463,304,446 outstanding, at march 31, 2021 and december 31, 2020, respectively | 31,794,000 | |||||||||||||||||
| short-term investments | ||||||||||||||||||
| total current assets: | 202,504,000 | |||||||||||||||||
| ordinary £0.05 par value shares; 488,304,446 and 105,326,638 issued, and 463,304,446 and 105,326,638 outstanding, at december 31, 2020 and 2019, respectively | 31,794,000 |
We provide you with 20 years of balance sheets for Verona Pharma plc stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Verona Pharma plc. Explore the full financial landscape of Verona Pharma plc stock with our expertly curated balance sheets.
The information provided in this report about Verona Pharma plc stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.